AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab

Oncotarget

Volumn 6, Issue 13, 2015, Pages 11507-11518

  Li, Xinqun ^a   Lu, Yang ^a   Lu, Haiquan ^a   Luo, Jingtao ^a,b   Hong, Yun ^a,c   Fan, Zhen ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

AMPK; Cancer metabolism; Cetuximab; EGFR; HIF 1

Indexed keywords

ADENYLATE KINASE; CETUXIMAB; HYPOXIA INDUCIBLE FACTOR 1; PROTEIN KINASE LKB1; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; HIF1A PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; STK11 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL LEVEL; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; METABOLIC REGULATION; MOLECULAR DYNAMICS; OSCILLATION; PROTEIN DETERMINATION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; HEAD AND NECK NEOPLASMS; HOMEOSTASIS; HUMAN; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TIME FACTOR; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CETUXIMAB; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENERGY METABOLISM; ENZYME ACTIVATION; HEAD AND NECK NEOPLASMS; HOMEOSTASIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84929649410     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3432     Document Type: Article

References (50)

1. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 2006; 7:505-516.
2. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008; 358:1160-1174.
3. Dhomen NS, Mariadason J, Tebbutt N, Scott AM. Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev. Oncog. 2012; 17:31-50.
4. Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 2013; 19:1389-1400.
5. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 2010; 7:493-507.
6. Diaz LA Jr., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012; 486:537-540.
7. Misale S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012; 486:532-536.
8. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008; 13:472-482.
9. Pan JG, Mak TW. Metabolic targeting as an anticancer strategy: dawn of a new era? Sci. STKE. 2007; 2007:e14.
10. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer. 2010; 10:267-277.
11. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 2011; 10:671-684.
12. Mullen AR, DeBerardinis RJ. Genetically-defined metabolic reprogramming in cancer. Trends Endocrinol. Metab. 2012; 23:552-559.
13. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat. Rev. Cancer. 2011; 11:85-95.
14. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324:1029-1033.
15. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, Christofk HR, Wagner G, Rabinowitz JD, Asara JM, Cantley LC. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science. 2010; 329:1492-1499.
16. Luwor RB, Lu Y, Li X, Mendelsohn J, Fan Z. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene. 2005; 24:4433-4441.
17. Li X, Lu Y, Liang K, Pan T, Mendelsohn J, Fan Z. Requirement of hypoxia-inducible factor-1alpha downregulation in mediating the antitumor activity of the antiepidermal growth factor receptor monoclonal antibody cetuximab. Mol. Cancer Ther. 2008; 7:1207-1217.
18. Lu H, Li X, Luo Z, Liu J, Fan Z. Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated LDH-A. Mol. Cancer Ther. 2013; 12:2187-2199.
19. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway:metabolism and growth control in tumour suppression. Nat. Rev. Cancer. 2009; 9:563-575.
20. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011; 25:1895-1908.
21. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 2012; 13:251-262.
22. Zhou G, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001; 108:1167-1174.
23. Ha J, Daniel S, Broyles SS, Kim KH. Critical phosphorylation sites for acetyl-CoA carboxylase activity. J. Biol. Chem. 1994; 269:22162-22168.
24. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J Med. 2004; 351:337-345.
25. Lievre A, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006; 66:3992-3995.
26. Khambata-Ford S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 2007; 25:3230-3237.
27. Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, Mendelsohn J, Fan Z. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res. 2007; 67:8240-8247.
28. Carling D, Zammit VA, Hardie DG. A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett. 1987; 223:217-222.
29. Li Y, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 2011; 13:376-388.
30. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003; 115:577-590.
31. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell. 2008; 30:214-226.
32. DeBerardinis RJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? Cell. 2012; 148:1132-1144.
33. Jiang L, DeBerardinis RJ. Cancer metabolism: When more is less. Nature. 2012; 489:511-512.
34. Egan DF, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science. 2011; 331:456-461.
35. Kim J, Kundu M, Viollet B, Guan KL. AMPK, and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 2011; 13:132-141.
36. Hardie DG. AMPK and autophagy get connected. EMBO J. 2011; 30:634-635.
37. Mizrachy-Schwartz S, Cohen N, Klein S, Kravchenko-Balasha N, Levitzki A. Up-regulation of AMP-activated protein kinase in cancer cell lines is mediated through c-Src activation. J Biol. Chem. 2011; 286:15268-15277.
38. Zou MH, Hou XY, Shi CM, Kirkpatick S, Liu F, Goldman MH, Cohen RA. Activation of 5′-AMP-activated kinase is mediated through c-Src and phosphoinositide 3-kinase activity during hypoxia-reoxygenation of bovine aortic endothelial cells. Role of peroxynitrite. J Biol. Chem. 2003; 278:34003-34010.
39. Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG, Schlattner U, Neumann D, Brownlee M, Freeman MB, Goldman MH. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol. Chem. 2004; 279:43940-43951.
40. Yamada E, Pessin JE, Kurland IJ, Schwartz GJ, Bastie CC. Fyn-dependent regulation of energy expenditure and body weight is mediated by tyrosine phosphorylation of LKB1. Cell Metab. 2010; 11:113-124.
41. Li X, Fan Z. The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1α and Bcl-2 and activating the Beclin 1/hVps34 complex. Cancer Res. 2010; 70:5942-5952.
42. Li X, Lu Y, Pan T, Fan Z. Roles of autophagy in cetuximabmediated cancer therapy against EGFR. Autophagy. 2010; 6:1066-1077.
43. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005; 310:1642-1646.
44. Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M, Wei L, Fishbein MC, Czernin J, Mischel PS, Shaw RJ. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell. 2013; 23:143-158.
45. Morgillo F, Sasso FC, Della Corte CM, Vitagliano D, D'Aiuto E, Troiani T, Martinelli E, De VF, Orditura M, De PR, Ciardiello F. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin. Cancer Res. 2013; 19:3508-3519.
46. Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol. 2014; 10:143-156.
47. Lu H, Liang K, Lu Y, Fan Z. The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1alpha. Cancer Lett. 2012; 322:78-85.
48. Zhao M, et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin. Cancer Res. 2011; 17:7248-7264.
49. Post DE, Van Meir EG. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther. 2001; 8:1801-1807.
50. Lu Y, Li X, Lu H, Fan Z. 1, 9-Pyrazoloanthrones downregulate HIF-1alpha and sensitize cancer cells to cetuximabmediated anti-EGFR therapy. PLoS One. 2010; 5:e58231.